Intuitive Surgical, Inc. (NASDAQ:ISRG) Position Boosted by Inspire Investing LLC

Inspire Investing LLC boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 32,718 shares of the medical equipment provider’s stock after acquiring an additional 667 shares during the period. Intuitive Surgical comprises approximately 1.6% of Inspire Investing LLC’s holdings, making the stock its 5th biggest holding. Inspire Investing LLC’s holdings in Intuitive Surgical were worth $16,073,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Ritholtz Wealth Management lifted its holdings in shares of Intuitive Surgical by 14.1% during the 3rd quarter. Ritholtz Wealth Management now owns 4,421 shares of the medical equipment provider’s stock worth $2,172,000 after acquiring an additional 546 shares during the period. Bennett Selby Investments LP acquired a new position in Intuitive Surgical during the third quarter worth approximately $212,000. Valeo Financial Advisors LLC raised its stake in Intuitive Surgical by 13.2% during the third quarter. Valeo Financial Advisors LLC now owns 4,119 shares of the medical equipment provider’s stock worth $2,023,000 after purchasing an additional 480 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Intuitive Surgical by 356.7% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,923 shares of the medical equipment provider’s stock valued at $1,436,000 after purchasing an additional 2,283 shares during the last quarter. Finally, Hilltop Wealth Advisors LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter valued at $866,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Up 0.2 %

Shares of ISRG opened at $484.78 on Friday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.48. The firm has a market cap of $172.27 billion, a price-to-earnings ratio of 83.30, a PEG ratio of 5.40 and a beta of 1.39. The business’s 50 day moving average is $480.34 and its two-hundred day moving average is $434.94.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.18 EPS. On average, equities analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ISRG has been the topic of several research reports. Royal Bank of Canada increased their target price on Intuitive Surgical from $515.00 to $525.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Stifel Nicolaus boosted their target price on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Evercore ISI raised their price target on shares of Intuitive Surgical from $410.00 to $475.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Robert W. Baird boosted their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Finally, Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their target price for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $458.35.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the transaction, the director now owns 821 shares of the company’s stock, valued at $402,519.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now owns 821 shares in the company, valued at $402,519.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares in the company, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,120 shares of company stock worth $25,528,753. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.